Crown Equity Holdings, Inc. (CRWE)
Crown Equity Holdings Inc., together with its digital network of Websites, offers media advertising, branding and marketing services as a worldwide online multi-media publisher. The company focuses on the distribution of information for the purpose of bringing together a targeted audience and the advertisers that want to reach them. Its advertising services cover and connect a range of marketing specialties, as well as providing search engine optimization for clients interested in online media awareness.
Crown Equity Holdings Inc. (CRWE.OB) announced that it has launched CRWE Tube, www.crwetube.com, a video sharing site that allows billions of people around the world to upload watch and share original videos.
“The CRWE Tube team has built an exciting media platform, which allows people and businesses large and small to quickly and efficiently reach a vast new audience,” said Kenneth Bosket, President of Crown Equity Holdings Inc. “With online videos continuing to experience explosive, viral growth and the web rapidly moving from text to video, businesses will need to adapt to the shift in video distribution technology or quickly become irrelevant to their consumers who anticipate seeing video everywhere online.”
Live videos will also be beneficial within the organization and the employees working with in the organization gets updated about the latest targets and goals of organization and sharing these information on the social networking sites like twitter, face book etc will be both beneficial to both employees as well as to the customers.
Live videos are also used for prelaunch of websites and products which describes the upcoming products and features. It has been found out that live videos are being watched by many users and should not be in a view that it is not taking away the industry of television.
People are making use of live videos on internet to see repeatedly whenever t hey like to see and hence it is becoming to turn down into a mini media on the internet and it is also attracting many viewers by giving answers to there questions lively.
For more information please visit official website of CRWE: www.crownequityholdings.com
Spectrum Pharmaceuticals, Inc. (Nasdaq:SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, announced that an overview of the Company’s business strategy will be given at the 30th Annual J. P. Morgan Healthcare Conference, being held at the Westin St. Francis Hotel in San Francisco, California. The Spectrum Pharmaceuticals presentation is at 11 am Pacific Time on Thursday, January 12, 2012 in the California East room.
Spectrum Pharmaceuticals, Inc., a commercial-stage biotechnology company, primarily focuses on oncology and hematology.
RTI Biologics, Inc. (Nasdaq:RTIX), a leading provider of orthopedic and other biologic implants, has launched an informational website to educate patients and the general public about allograft tissue. AllograftInfo.com explores the use of allograft, or human donated tissue, in surgery, as well as provides links to relevant research and articles. The website also addresses several frequently asked questions and provides suggestions on what to ask your surgeon when considering allograft.
RTI Biologics, Inc., together with its subsidiaries, produces orthopedic and other surgical implants that repair and promote the natural healing of human bone and other human tissues.
Isis Pharmaceuticals, Inc. (NASDAQ:ISIS) announced results from a Phase 1 study with ISIS-TTRRx. The results demonstrated that treatment with ISIS-TTRRx produced dose-dependent statistically significant reductions of greater than 80 percent in transthyretin (TTR) protein. In this study, ISIS-TTRRx was generally well tolerated with no significant adverse events. ISIS-TTRRx is an antisense drug in development with GlaxoSmithKline (GSK) for the treatment of TTR amyloidosis, a severe and rare genetic disease characterized by progressive dysfunction of peripheral nerve and/or heart tissues. Isis and GSK are planning to begin a clinical study on ISIS-TTRRx this year designed to achieve an efficient route to registration.
Isis Pharmaceuticals, Inc. engages in the discovery and development of antisense drugs using antisense drug discovery platform.
No comments:
Post a Comment